Oral therapy with β‐sitosterol‐d‐glucoside resulted in decreased tumor growth by hampering the PI3K–Akt pathway, reducing tumor‐associated antigens CEA, CA125, and CA153 levels, and elevating microRNA‐10a (miR‐10a) expression (Xu et al., 2018). Here, AKT1 is linked to neoplasm.